PDgrastim® 300 mcg


PDgrastim® contains G-CSF (Filgrastim), a colony stimulating factor.

PDgrastim® is supplied as 300µg filgrastim in a 0.5 mL prefilled syringe and ampoule for subcutaneous (SC) injection.

PDgrastim® is used for reduction the risk of infection in patients receiving strong chemotherapeutic agents.

PDgrastim® is used for neutropenia treatment.

PDgrastim® is a man-made form of granulocyte colony-stimulating factor (GCSF), which is produce using the bacteria E coli. G-CSF is a substance naturally produced by the body. It stimulates the growth of neutrophils.

Clinical pharmacology:

Granulocyte colony-stimulating factor; acts on hematopoietic cells by binding to specific cell surface receptors which regulates the production and release of functional neutrophils from the bone marrow.


PDgrastim® Clearance has been shown to follow first-order pharmacokinetics after subcutaneous and administration.

PDgrastim® elimination half-life: approximately 3.5 hours


  • Cancer Patients Receiving Myelosuppressive Chemotherapy
  • Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy
  • Cancer Patients Receiving Bone Marrow Transplant
  • Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy
  • Patients With Severe Chronic Neutropenia
  • mobilisation of peripheral blood progenitor cells (PBPCs)
  • increase neutrophil counts and reduce the incidence and duration of infection-related events In patients with severe congenital, cyclic, or idiopathic neutropenia and a history of severe or recurrent infections
  • treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/l) in patients with advanced HIV infection

Side effects:

Serious side effects:

Spleen rupture, serious allergic reactions, acute respiratory distress syndrome

Most common side effects:

Bone and muscle aching, injection site reactions (redness, swelling or aching), Headache, Fatigue

Drug interaction:

Drugs such as lithium may potentiate the release of neutrophils; patients receiving lithium and PDgastrim® should have more frequent monitoring of neutrophil counts.

Monitoring parameters:

  • CBC with differential and platelets prior to treatment and periodically during the treatment
  • In congenital neutropenia monitor Bone marrow and karyotype prior to treatment; and monitor marrow and cytogenetics annually throughout treatment
  • Temperature